4.5 Article

Vitamins B12, B6, and folic acid for onset of depressive symptoms in older men:: Results from a 2-year placebo-controlled randomized trial

Journal

JOURNAL OF CLINICAL PSYCHIATRY
Volume 69, Issue 8, Pages 1203-1209

Publisher

PHYSICIANS POSTGRADUATE PRESS
DOI: 10.4088/JCP.v69n0801

Keywords

-

Ask authors/readers for more resources

Objective: To examine whether use of vitamins B-12, B-6, and folate was associated with reduced severity of depressive symptoms and 2-year incidence of clinically significant depression. Method: The investigators recruited 299 men aged 75 years and older free of clinically significant depression (Beck Depression Inventory [BDI] score < 18). They were randomly assigned to treatment with 400 mu g B-12 + 2 mg folic acid + 25 mg B-6 per day (N = 150) or placebo (N = 149). The BDI was the primary outcome measure of the Study. Follow-tip assessments took place 6, 12, 18, and 24 months after baseline. Analyses were intention-to-treat. The study was conducted from June 2001 to June 2004. Results: 118 and 123 men treated with vitamins and placebo, respectively, completed this 2-year trial (19.4% dropout rate). Analysis of variance for repeated measures showed that there was no difference between the groups (F = 0.76, df = 1, p = .384) nor was there it significant change of BDI scores over time (F = 1.26, df = 4, p = .284). Cox regression revealed that participants treated with vitamins were 24% more likely to remain free of depression during the trial, although the difference between groups was not significant (95% CI = 0.68 to 2.28). At the end of the study, 84.3% of men treated with vitamins and 79.1% of those treated with placebo remained free of clinically significant depressive symptoms. The number of people needed to treat to show benefit was 21. Conclusion: The results of this study showed that treatment with B-12, folic acid, and B-6 is no better than placebo at reducing the severity of depressive symptoms or the incidence of clinically significant depression over a period of 2 years in older men. Trial Registration: www.anzctr.org.au Identifier: ACTRN012605000045617.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available